Obesity As a Risk Factor for Neuropathy: a Case-control Study

Overview

Journal Hormones (Athens)

Specialty Endocrinology

Date 2024 Nov 22

PMID 39576448

Authors

Esra Ersan Tomo

Hacer Hicran Mutlu

Hasan Huseyin Mutlu

Affiliations

Soon will be listed here.

Abstract

Aim: Neuropathy, a common complication of diabetes associated with metabolic issues, lacks clarity regarding its prevalence in metabolically healthy obese versus non-obese individuals. Our study aims to compare neuropathy rates between those with and those without obesity and who are metabolically healthy.

Methods: We included individuals aged 20-50, one group with a body mass index (BMI) ≥ 30 kg/m² (metabolically healthy and obese) and another with a BMI < 30 kg/m² (metabolically healthy and non-obese). Exclusion criteria encompassed diabetes, hypertension, chronic renal disease, vitamin B12 deficiency, anemia, primary amyloidosis, immune system disorders, malignancy, active infection, and paraneoplastic syndromes. Patients underwent assessments using the Neuropathy Symptom Score (NSS) and modified Neuropathy Disability Score (mNDS).

Results: The median scores for NSS and mNDS were higher among metabolically healthy obese individuals than non-obese participants (2 (1-4) vs. 0 (0-1) for NSS; p < 0.001 and 4 (2-5) vs. 2 (1-4) for mNDS; p < 0.001). Individuals with obesity had a 110.09 times higher likelihood of experiencing neuropathy compared to those without obesity. The severity of neuropathy was significantly greater in the metabolically healthy group with obesity. There were no statistically significant differences in anthropometric and laboratory values between participants with and without neuropathy, except for triglyceride levels. Patients with neuropathy exhibited higher triglyceride levels compared to those without neuropathy.

Conclusion: Our study demonstrated a higher prevalence of neuropathy among metabolically healthy obese individuals in comparison to those who were metabolically healthy and non-obese.

References

Smith A, Singleton J . Obesity and hyperlipidemia are risk factors for early diabetic neuropathy. J Diabetes Complications. 2013; 27(5):436-42. PMC: 3766404. DOI: 10.1016/j.jdiacomp.2013.04.003. View

Stino A, Smith A . Peripheral neuropathy in prediabetes and the metabolic syndrome. J Diabetes Investig. 2017; 8(5):646-655. PMC: 5583955. DOI: 10.1111/jdi.12650. View

Hyllienmark L, Alstrand N, Jonsson B, Ludvigsson J, Cooray G, Wahlberg-Topp J . Early electrophysiological abnormalities and clinical neuropathy: a prospective study in patients with type 1 diabetes. Diabetes Care. 2013; 36(10):3187-94. PMC: 3781488. DOI: 10.2337/dc12-2226. View

Ortega F, Lee D, Katzmarzyk P, Ruiz J, Sui X, Church T . The intriguing metabolically healthy but obese phenotype: cardiovascular prognosis and role of fitness. Eur Heart J. 2012; 34(5):389-97. PMC: 3561613. DOI: 10.1093/eurheartj/ehs174. View

Miscio G, Guastamacchia G, Brunani A, Priano L, Baudo S, Mauro A . Obesity and peripheral neuropathy risk: a dangerous liaison. J Peripher Nerv Syst. 2005; 10(4):354-8. DOI: 10.1111/j.1085-9489.2005.00047.x. View

Sajdyk T, Boyle F, Foran K, Tong Y, Pandya P, Smith E . Obesity as a Potential Risk Factor for Vincristine-induced Peripheral Neuropathy. J Pediatr Hematol Oncol. 2019; 42(7):e637-e640. PMC: 7165027. DOI: 10.1097/MPH.0000000000001604. View

Bell J, Kivimaki M, Hamer M . Metabolically healthy obesity and risk of incident type 2 diabetes: a meta-analysis of prospective cohort studies. Obes Rev. 2014; 15(6):504-15. PMC: 4309497. DOI: 10.1111/obr.12157. View

Callaghan B, Xia R, Reynolds E, Banerjee M, Rothberg A, Burant C . Association Between Metabolic Syndrome Components and Polyneuropathy in an Obese Population. JAMA Neurol. 2016; 73(12):1468-1476. PMC: 5217829. DOI: 10.1001/jamaneurol.2016.3745. View

10.

Obrosova I, Ilnytska O, Lyzogubov V, Pavlov I, Mashtalir N, Nadler J . High-fat diet induced neuropathy of pre-diabetes and obesity: effects of "healthy" diet and aldose reductase inhibition. Diabetes. 2007; 56(10):2598-608. DOI: 10.2337/db06-1176. View

11.

Feldman E, Callaghan B, Pop-Busui R, Zochodne D, Wright D, Bennett D . Diabetic neuropathy. Nat Rev Dis Primers. 2019; 5(1):41. DOI: 10.1038/s41572-019-0092-1. View

12.

Azmi S, Ferdousi M, Liu Y, Adam S, Siahmansur T, Ponirakis G . The role of abnormalities of lipoproteins and HDL functionality in small fibre dysfunction in people with severe obesity. Sci Rep. 2021; 11(1):12573. PMC: 8206256. DOI: 10.1038/s41598-021-90346-9. View

13.

Grisold A, Callaghan B, Feldman E . Mediators of diabetic neuropathy: is hyperglycemia the only culprit?. Curr Opin Endocrinol Diabetes Obes. 2017; 24(2):103-111. PMC: 5831542. DOI: 10.1097/MED.0000000000000320. View

14.

Wiggin T, Sullivan K, Pop-Busui R, Amato A, Sima A, Feldman E . Elevated triglycerides correlate with progression of diabetic neuropathy. Diabetes. 2009; 58(7):1634-40. PMC: 2699859. DOI: 10.2337/db08-1771. View

15.

Tesfaye S, Chaturvedi N, Eaton S, Ward J, Manes C, Ionescu-Tirgoviste C . Vascular risk factors and diabetic neuropathy. N Engl J Med. 2005; 352(4):341-50. DOI: 10.1056/NEJMoa032782. View

16.

Maeda T, Kiguchi N, Kobayashi Y, Ikuta T, Ozaki M, Kishioka S . Leptin derived from adipocytes in injured peripheral nerves facilitates development of neuropathic pain via macrophage stimulation. Proc Natl Acad Sci U S A. 2009; 106(31):13076-81. PMC: 2722338. DOI: 10.1073/pnas.0903524106. View

17.

Vincent A, Hayes J, McLean L, Vivekanandan-Giri A, Pennathur S, Feldman E . Dyslipidemia-induced neuropathy in mice: the role of oxLDL/LOX-1. Diabetes. 2009; 58(10):2376-85. PMC: 2750230. DOI: 10.2337/db09-0047. View

18.

Wu T, Su G, Liu T, Wang H, Hwu C . Urinary acrolein protein conjugates-to-creatinine ratio is positively associated with diabetic peripheral neuropathy in patients with type 2 diabetes mellitus. Endocr Connect. 2023; 12(11). PMC: 10563594. DOI: 10.1530/EC-23-0253. View